Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

Trastuzumab is a remarkably effective therapy for patients with human epidermal growth factor receptor 2 (HER2) - positive breast cancer (BC). However, not all women with high levels of HER2 benefit from trastuzumab.

Bibliographic Details
Main Authors: Sonnenblick, Amir, Brohée, Sylvain, Fumagalli, Debora, Rothé, Françoise, Vincent, Delphine, Ignatiadis, Michael, Desmedt, Christine, Salgado, Roberto, Sirtaine, Nicolas, Loi, Sherene, Neven, Patrick, Loibl, Sibylle, Denkert, Carsten, Joensuu, Heikki, Piccart, Martine, Sotiriou, Christos
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745800/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745800/

Similar Items